Publications by authors named "K M Muraszko"
Tissue-agnostic, molecularly targeted therapies are becoming increasingly common in cancer treatment. The molecular drivers of some classes and subclasses of tumors are rapidly being uncovered in an era of deep tumor sequencing occurring at the time of diagnosis. When and how targeted therapies should fit within up-front cytotoxic chemotherapy and radiation paradigms is yet to be determined, because many of them have been studied in single-arm studies in patients with relapsed or refractory cancer.
View Article and Find Full Text PDFBackground: Patients are commonly monitored for hyponatremia after intracranial procedures, yet the prevalence of hyponatremia after cranial vault reconstruction (CVR) remains unclear. The purpose of this study is to define the prevalence, risk factors, and complications of hyponatremia after CVR to optimize postoperative sodium surveillance protocols.
Methods: Patients with nonsyndromic, single-suture craniosynostosis who underwent primary CVR between 2009 and 2020 at Michigan Medicine were included (n = 231).
Objective: Given the lack of a definitive treatment and the poor prognosis of patients with diffuse midline glioma (DMG) and diffuse intrinsic pontine glioma (DIPG), socioeconomic status (SES) may affect treatment access and therefore survival. Therefore, this study aimed to examine the relationship between SES and treatment modalities, progression-free survival (PFS), and overall survival (OS) in children with DMG/DIPG.
Methods: A retrospective, single-institution review was conducted of medical records of patients ≤ 18 years of age who had DMG or DIPG that was diagnosed between 2000 and 2022.
Article Synopsis
- - Recent clinical trials for H3K27-altered diffuse midline gliomas (DMGs) are showing promising results, indicating potential advancements in treatment.
- - The text identifies three key challenges: improving experimental models to include immune and brain-specific factors, fostering collaboration between researchers, clinicians, and the industry, and optimizing clinical processes like biopsy and drug delivery.
- - Emphasizes that extensive collaboration is crucial for enhancing our understanding of DMGs, as well as improving diagnostics and therapies for these tumors.
Article Synopsis
- This study focuses on a clinical trial exploring the use of adenoviral vectors to enhance immune responses in patients with high-grade gliomas, which are aggressive brain tumors with poor treatment outcomes.
- The trial involved administering two specific vectors (HSV1-TK and Flt3L) into the tumor site of treatment-naive adults, using a dose-finding approach to evaluate safety and potential effectiveness.
- Conducted at the University of Michigan, the study aimed to assess how these vectors could stimulate anti-tumor immunity and improve patient prognosis after standard treatment protocols.